- Home
- ACCD vs ENGN Comparison
ACCD vs ENGN Comparison
Compare ACCD & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACCD
- ENGN
- Stock Information
- Founded
- ACCD 2007
- ENGN 1999
- Country
- ACCD United States
- ENGN Canada
- Employees
- ACCD N/A
- ENGN N/A
- Industry
- ACCD Business Services
- ENGN
- Sector
- ACCD Consumer Discretionary
- ENGN
- Exchange
- ACCD Nasdaq
- ENGN Nasdaq
- Market Cap
- ACCD 281.1M
- ENGN 317.6M
- IPO Year
- ACCD 2020
- ENGN N/A
- Fundamental
- Price
- ACCD $6.93
- ENGN $6.29
- Analyst Decision
- ACCD Hold
- ENGN Buy
- Analyst Count
- ACCD 11
- ENGN 10
- Target Price
- ACCD $6.22
- ENGN $26.40
- AVG Volume (30 Days)
- ACCD 1.7M
- ENGN 179.7K
- Earning Date
- ACCD 01-10-2025
- ENGN 03-10-2025
- Dividend Yield
- ACCD N/A
- ENGN N/A
- EPS Growth
- ACCD N/A
- ENGN N/A
- EPS
- ACCD N/A
- ENGN N/A
- Revenue
- ACCD $446,718,000.00
- ENGN N/A
- Revenue This Year
- ACCD $14.47
- ENGN N/A
- Revenue Next Year
- ACCD $12.51
- ENGN N/A
- P/E Ratio
- ACCD N/A
- ENGN N/A
- Revenue Growth
- ACCD 14.99
- ENGN N/A
- 52 Week Low
- ACCD $3.08
- ENGN $4.42
- 52 Week High
- ACCD $11.16
- ENGN $18.40
- Technical
- Relative Strength Index (RSI)
- ACCD 81.29
- ENGN 44.90
- Support Level
- ACCD $6.86
- ENGN $5.51
- Resistance Level
- ACCD $6.93
- ENGN $7.00
- Average True Range (ATR)
- ACCD 0.04
- ENGN 0.74
- MACD
- ACCD -0.10
- ENGN -0.01
- Stochastic Oscillator
- ACCD 78.95
- ENGN 43.43
About ACCD Accolade Inc.
Accolade Inc offers technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. The company's platform combines open, cloud-based intelligent technology with multimodal support from a team of Accolade Care Advocates and clinicians, including registered nurses, physician medical directors, pharmacists, primary care physicians, and other professionals to provide advocacy, medical opinion, and virtual primary care services.
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.